Overcoming cellular senescence in human cancer pathogenesis

Genes and Development - Tập 12 Số 2 - Trang 163-174 - 1998
Thomas R. Yeager1, Sandy DeVries2, David F. Jarrard3,4, Chinghai Kao5, Stephen Y. Nakada3,4, Timothy D. Moon3,4, Reginald C. Bruskewitz3,4, Walter M. Stadler6, Lorraine F. Meisner7, Kennedy W. Gilchrist8,4, Michael A. Newton9, Frederic M. Waldman2, Catherine A. Reznikoff10,4
1Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53792 USA
2Department of Laboratory Medicine and Division of Molecular Cytometry, University of California at San Francisco, San Francisco, California 94143 USA
3Surgery
4University of Wisconsin Comprehensive Cancer Center and University of Wisconsin Medical School,
5Department of Urology, University of Virginia, Charlottesville, Virginia 22908 USA;
6Department of Hematology/Oncology, University of Chicago, Chicago, Illinois 60637 USA;
7State Laboratory of Hygiene, Madison, Wisconsin 53792 USA;
8Pathology, and
9Biostatistics
10Program in Cellular and Molecular Biology, and

Tóm tắt

Elevation of p16, the CDKN2/p16 tumor suppressor gene (TSG) product, occurs at senescence in normal human uroepithelial cells (HUC). Immortal HUCs and bladder cancer cell lines show either alteration of p16 or pRb, the product of the retinoblastoma (RB) TSG. In addition, many human cancers show p16 or pRb alteration along with other genetic alterations that we associated with immortalization, including +20q and −3p. These observations led us to hypothesize that p16 elevation plays a critical role in senescence cell cycle arrest and that overcoming this block is an important step in tumorigenesis in vivo, as well as immortalization in vitro. Using a novel approach, we tested these hypotheses in the present study by examining p16 and pRb status in primary culture (P0) and after passage in vitro of transitional cell carcinoma (TCC) biopsies that represented both superficial bladder tumors and invasive bladder cancers. We demonstrated that all superficial TCCs showed elevated p16 after limited passage in vitro and then senesced, like normal HUCs. In contrast, all muscle invasive TCCs contained either a p16 or a pRb alteration at P0 and all spontaneously bypassed senescence (P = 0.001). Comparative genomic hybridization (CGH) was used to identify regions of chromosome loss or gain in all TCC samples. The application of a statistical model to the CGH data showed a high probability of elevated alteration rates of +20q11−q12 (0.99) and +8p22−pter (0.94) in the immortal muscle invasive TCCs, and of −9q (0.99) in the superficial TCCs. Three myoinvasive TCCs lost 3p13−p14. In this study, four of six myoinvasive TCCs also showedTP53 mutation that associated well with genome instability (P = 0.001), as previously hypothesized. Notably,TP53 mutation, which has been used as a marker of tumor progression in many human cancers, was less significant in associating with progression in this study (P = 0.04) than was p16 or pRb alteration (P = 0.001). Thus, these data support a new model in which overcoming senescence plays a critical role in human cancer pathogenesis and requires at least two genetic changes that occur in several combinations that can include either p16 or pRb loss and at least one additional alteration, such as +20q11−q12, −3p13−p14, or −8p21−pter.

Từ khóa


Tài liệu tham khảo

American Cancer Society (1997) Cancer facts and figures—1996, 96-300M–No. 5008.96. (American Cancer Society, Bethesda, MD).

10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.0.CO;2-W

Bane, 1996, Pathology and staging of bladder cancer., Semin. Oncol., 23, 546

Belair, C.D., T.R. Yeager, P.M. Lopez, and C.A. Reznikoff. 1997. Telomerase activity: A biomarker for proliferation—not malignant transformation. Proc. Natl. Acad. Sci. (in press)..

10.1126/science.8023167

10.1038/ng1095-210

Catalona, W.J. 1992. Urothelial tumors of the urinary tract. InCampbell’s Urology (ed. P.C. Walsh, A.B. Retik, T.A. Stamey, and E.D. Vaughn), Chapter 28, pp. 1094–1158. W.B. Sanders, Philadelphia, PA..

Cordon-Cardo, 1997, Cooperative effects of p53 and pRb alteration in primary superficial bladder tumors., Cancer Res., 57, 1217

10.1101/SQB.1994.059.01.010

10.1073/pnas.92.20.9363

Efron B. Tibshirani R. (1993) An introduction to the bootstrap. (Chapman and Hall, London, UK).

10.1056/NEJM199411103311903

Gonzalez-Zulueta, 1995, Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing., Cancer Res., 55, 4531

Harley C.B. (1995) Telomeres and aging. in Telomeres, eds Blackburn E.H. Greider C.W (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY), pp 247–263.

Hayflick, 1974, The longevity of cultured human cells., Assoc. Am. Geriatr. Soc., 22L, 1

10.1126/science.1905840

Hubuchi, 1993, Accumulated allelic losses in the development of urothelial cancer., Int. J. Cancer, 53, 579, 10.1002/ijc.2910530409

10.1002/gcc.2870120309

Kamb, 1994, A cell cycle regulator potentially involved in genesis of many tumor types., Science, 264, 463, 10.1126/science.8153634

Kannio, 1996, A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking and occupational exposure to asbestos., Cancer Epidemiol. Biomarkers Prev., 5, 33

Knowles, 1994, Allelotype of human bladder cancer., Cancer Res., 54, 531

10.1038/36462

10.1038/375503a0

10.1073/pnas.92.14.6289

10.1038/nm0795-686

Mertens, 1997, Chromosome imbalance maps of malignant solid tumors: A cytologic survey of 3185 neoplasims., Cancer Res., 57, 2765

10.1016/S0092-8674(00)80538-3

10.1002/sim.4780130805

Nseyo, 1996, Therapy of superficial bladder cancer., Semin. Oncol., 23, 598

Ohta, 1997, Overexpressed cyclin D1 protein related to p53 and retinoblastoma proteins in translational cell carcinoma of the urinary tract., Oncology Rep., 4, 97

10.1016/0304-3835(96)04225-5

Presti, 1991, Molecular genetic alterations in superficial and locally advanced human bladder cancer., Cancer Res., 51, 5405

Reznikoff, 1983, Altered growth patterns in vitro of human papillary transitional carcinoma cells., Am. J. Pathol., 111, 263

10.1002/jcp.1041310302

10.1101/gad.8.18.2227

Reznikoff, 1996, A molecular genetic model of human bladder cancer pathogenesis., Semin. Oncol., 23, 571

Reznikoff, 1996, Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human urothelial cells., Cancer Res., 56, 2886

Ross, 1996, Bladder cancer epidemiology and pathogenesis., Semin. Oncol., 23, 536

10.1093/jnci/85.1.53

10.1038/sj.onc.1200868

10.1038/366704a0

10.1016/S0092-8674(00)81902-9

Shin, 1997, Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers., Br. J. Cancer, 75, 1788, 10.1038/bjc.1997.305

10.1038/sj.onc.1201066

Spruck, 1994, Two molecular pathways to transitional cell carcinoma of the bladder., Cancer Res., 54, 784

10.1038/370183a0

Takle, 1996, Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer., Oncogene, 12, 1083

Vieten, L., C.D. Belair, L. Savelieva, K. Julicher, F. Broker, W. Bardenheuer, and J. Schuttee. 1997. Minimal deletion of 3p13 → p14.2 associated with immortalization of human uroepithelial cells. Genes, Chrom. Cancer (in press)..

Xu, 1993, Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression., Int. J. Cancer, 53, 781, 10.1002/ijc.2910530513

Yeager, 1995, Increased p16 levels correlate with pRb alterations in human urothelial cells., Cancer Res., 55, 493

Thông tin
Thông tin xuất bản

Genes and Development

Tập 12 Số 2

163-174

Thông tin tác giả